|
1) Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010; 139: 1246-56, 1256 e1-5
|
|
|
|
|
2) Gustot T, Durand F, Lebrec D, et al. Severe sepsis in cirrhosis. Hepatology. 2009; 50: 2022-33
|
|
|
|
|
3) Cazzaniga M, Dionigi E, Gobbo G, et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol. 2009; 51: 475-82
|
|
|
|
|
|
4) Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011; 33: 739-47
|
|
|
|
|
|
5) Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010; 53: 849-55
|
|
|
|
|
|
6) Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010; 138: 2332-40
|
|
|
|
|
|
7) Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011; 140: 478-87
|
|
|
|
|
|
8) Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011; 106: 307-16
|
|
|
|
|
|
9) Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362: 1071-81
|
|
|
|
|
|
10) Les I, Doval E, Garcia-Martinez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011; 106: 1081-8
|
|
|
|
|
|
11) Bellot P, Garcia-Pagan JC, Frances R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010; 52: 2044-52
|
|
|
|
|
|
12) Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010; 55: 1465-71
|
|
|
|
|
|
13) Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed？ Am J Gastroenterol. 2010; 105: 323-7
|
|
|
|
|
|
14) Kim BI, Kim HJ, Park JH, et al. Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage. J Gastroenterol Hepatol. 2011; 26: 550-7
|
|
|
|
|
|
15) Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010; 51: 1327-33
|
|
|
|
|
|
16) Guarner-Argente C, Sanchez E, Vidal S, et al. Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther. 2010; 31: 1192-9
|
|
|
|
|
|
17) Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promotor and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011; 55: 1010-6
|
|
|
|
|
|
18) Gines P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010; 31: 834-45
|
|
|
|
|
|
19) Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010; 53: 283-90
|
|
|
|
|
|
20) Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010; 45: 979-87
|
|
|
|
|
21) Angeli P, Fasolato S, Mazza E, et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut. 2010; 59: 98-104
|
|
|
|
|
|
22) Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49: 2087-107
|
|
|
|
|
|
23) Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52: 1017-22
|
|
|
|
|
|
24) Serste T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. J Hepatol. 2011; 55: 794-9
|
|
|
|
|
|
25) Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe？ Hepatology. 2010; 52: 811-3
|
|
|
|
|
|
26) Angeli P. β-blockers and refractory ascites in cirrhosis: The message of a team of true scientists. J Hepatol 2011; 55: 743-4
|
|
|
|
|
|
27) Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011; 54: 555-61
|
|
|
|
|